GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis study tests whether adding low-dose radiation and an immunotherapy drug (tislelizumab) to standard chemotherapy improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will receive either the combination or chemo…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 02, 2026 07:52 UTC
-
New drug cocktail aims to wipe out stomach tumors before surgery
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (lenvatinib) in 20 people with a specific type of advanced stomach or gastroesophageal junction cancer (MSI-H/dMMR). The goal is to see if this treatm…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC